61 year old male with alcohol-related cirrhosis presents with severe ascites. He had a therapeutic paracentesis with improvement in his ascites and underwent a surveillance EGD which showed large...
Tom Couri
Treatment options for HRS type-1 are limited and prior data for terlipressin was mixed. This RCT tried to shed further light on the efficacy of terlipressin. https://www.nejm.org/doi/full/10.1056...
Lizzie Aby
Lactulose and Rifaximin (Xifaxan) are standards of care for the prevention of overt hepatic encephalopathy in patients with cirrhosis. Have you ever wondered why? Join us! First, if you want a...
Alyson Kaplan
Adam and Alex talk with Dr. Elliot Tapper about mentorship and MedEd in a July 1 special.
Adam Winters
Alex Vogel
In a follow-up to an outstanding overview of NSBB therapy in liver disease, Part 2 of this series by Anahita Rabiee presents evidence in support of earlier use of NSBBs in cirrhosis. Read on!
Anahita Rabiee
In the first post from new LFN author Anahita Rabiee, we are gifted an authoritative review on the Whys and Hows of beta-blockade in decompensated cirrhosis! You definitely want to read this one!
Can beta-blockade in patients with clinically significant portal hypertension prevent decompensations? The PREDESCI trial sought out to determine just that!
In part 2 of our coagulopathy series, we take a deeper dive and learn the ways in which end-stage liver disease alters the body's normal hemostatic mechanisms.
Hersh Shroff
A 60-year-old male with a history of HBV exposure, HCV with spontaneous clearance, and myelofibrosis with transfusion-dependent pancytopenia presents with tense ascites and coffee ground emesis. On...
Sarang Thaker
Patients with end-stage liver disease have elevated INRs. They bleed frequently and they clot perhaps more frequently. Do they need FFP before a paracentesis? What's a TEG? These questions answered...
Enter your email here and receive monthly newsletters with new LFN material.
Registration failed. Please try again later.
